Barometer Capital Management Inc. acquired a new stake in shares of argenex SE (NASDAQ:ARGX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,550 shares of the company's stock, valued at approximately $1,132,000.
Other institutional investors have also recently made changes to their positions in the company. Abound Wealth Management lifted its position in shares of argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company's stock worth $28,000 after buying an additional 32 shares in the last quarter. Sound Income Strategies LLC purchased a new position in argenex during the 4th quarter valued at approximately $28,000. Whipplewood Advisors LLC purchased a new position in argenex during the 1st quarter valued at approximately $28,000. Sunbelt Securities Inc. bought a new stake in argenex in the 3rd quarter worth approximately $36,000. Finally, Aventura Private Wealth LLC bought a new stake in argenex in the 4th quarter worth approximately $38,000. Hedge funds and other institutional investors own 60.32% of the company's stock.
argenex Trading Up 3.4%
Shares of NASDAQ ARGX opened at $874.74 on Wednesday. argenex SE has a 12-month low of $563.08 and a 12-month high of $953.58. The stock's fifty day simple moving average is $862.87 and its two-hundred day simple moving average is $813.72. The stock has a market capitalization of $54.72 billion, a PE ratio of 38.95, a price-to-earnings-growth ratio of 1.05 and a beta of 0.45.
argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The business had revenue of $1.31 billion for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. On average, equities analysts predict that argenex SE will post 26.27 earnings per share for the current fiscal year.
Analyst Ratings Changes
ARGX has been the subject of a number of research reports. Oppenheimer lowered their target price on argenex from $1,060.00 to $1,014.00 and set an "outperform" rating for the company in a research report on Thursday, April 2nd. HC Wainwright restated a "buy" rating and issued a $940.00 price target on shares of argenex in a research report on Thursday, June 25th. Royal Bank Of Canada upped their price target on shares of argenex from $890.00 to $945.00 and gave the company an "outperform" rating in a research note on Tuesday, July 7th. Wedbush reiterated an "outperform" rating and set a $1,000.00 price objective on shares of argenex in a research report on Thursday, June 11th. Finally, Guggenheim boosted their target price on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a "buy" rating in a report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $1,042.67.
Read Our Latest Research Report on argenex
argenex Company Profile
(
Free Report)
argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider argenex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenex wasn't on the list.
While argenex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
